Fig. 1: Patient disposition. | Nature Communications

Fig. 1: Patient disposition.

From: Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Fig. 1: Patient disposition.The alternative text for this image may have been generated using AI.

CONSORT flow diagram of patient disposition and eligibility in the analysis of mechanisms of acquired resistance in the AURA3 trial. *Plasma provided at baseline and at disease progression or treatment discontinuation. EGFR epidermal growth factor receptor, p.o, orally, qd once daily, TKI tyrosine kinase inhibitor.

Back to article page